Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Positive Development for Bristol-Myers Squibb Company's Breyanzi NHL Treatment

March 19, 2025
Bristol-Myers Squibb Company's groundbreaking NHL treatment, Breyanzi, has received approval from the European Commission (EC) for its use in patients. This approval is a significant milestone for the pharmaceutical company as it expands its reach in the European market. Breyanzi has shown promising results in clinical trials, providing hope for patients with NHL. With this latest development, Bristol-Myers Squibb Company is expected to witness a surge in demand for its innovative treatment. Investors and healthcare professionals are advised to consult the experts at Stocks Prognosis for accurate forecasts on the movement of Bristol-Myers Squibb Company's shares.
If you want to leave a comment, then you need Login or Register





Other data for BMY

Related data

BMYJuly 31, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target Forecast with 11.1% Profit Achieved  ~1 min.

On April 16, 2025, QuantWave issued a short forecast signal for BRISTOL-MYERS SQUIBB COMPANY with a price of 48.72 $. Fast forward to July 31, 2025, the target price of 43....


BMYJuly 31, 2025BRISTOL-MYERS SQUIBB COMPANY Stock Hits Forecast Price Target with 10.86% Profit  ~1 min.

QuantWave, an automated forecasting platform, recently achieved a milestone in its prediction accuracy with the successful forecast of BRISTOL-MYERS SQUIBB COMPANY's stock movement....


BMYJune 23, 2025Bristol Myers Squibb NYSE:BMY Set to Revolutionize Cancer Treatment with Breakthrough Drug  ~1 min.

Bristol Myers Squibb Company, a leading pharmaceutical company, is on the verge of revolutionizing cancer treatment with its groundbreaking new drug....


BMYJune 12, 2025BMY: Bristol-Myers Squibb Co. Reports Positive Phase 3 Trial Results For Sotyktu  ~1 min.

Investors are taking notice of Bristol-Myers Squibb Company, as they have recently announced positive phase 3 trial results for their drug Sotyktu. This news has caused BMY shares to rise by 3....


BMYMay 14, 2025QuantWave Successfully Achieves Price Target Forecast for Bristol-Myers Squibb Company with 14.06% Profit  ~2 min.

QuantWave, an automated forecasting platform, recently celebrated a significant achievement in its analytics with the successful price target forecast for the stock of BRISTOL-MYERS SQUIBB COMPANY....


BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits QuantWave Price Target with 13.0% Profit Margin  ~2 min.

On April 11, 2025, QuantWave, an automated forecasting platform, released a short signal for BRISTOL-MYERS SQUIBB COMPANY with a price target forecast of 44.12 $, indicating a 13....


BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Stock Hits Price Target with 9.09% Profit: QuantWave Forecast Success  ~2 min.

On April 23, 2025, QuantWave's forecasting platform generated a short signal for BRISTOL-MYERS SQUIBB COMPANY stock, which was trading at $47.9 at the time....


BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target Forecast with 12.75% Profit - QuantWave Analysis  ~1 min.

BRISTOL-MYERS SQUIBB COMPANY recently achieved the price target forecast set by QuantWave, resulting in a profitable outcome of 12.75%....


BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target Forecast with 11.87% Profit  ~1 min.

On May 5, 2025, QuantWave issued a short signal for BRISTOL-MYERS SQUIBB COMPANY when the stock was trading at $49.41. The forecast proved accurate as the price target of $43....


BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target Forecast with 11.76% Profit  ~1 min.

On April 15, 2025, QuantWave, the automated forecasting platform, issued a short signal for BRISTOL-MYERS SQUIBB COMPANY when the stock was trading at $49.35....


REGNJanuary 1, 2025Regeneron Pharmaceuticals Inc. Shows Impressive 89% Return for Investors  ~1 min.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been making significant strides in the pharmaceutical industry, resulting in a decent 89% return for its investors over the last five years....


REGNJanuary 1, 2025Regeneron Pharmaceuticals, Inc.: Groundbreaking Discoveries in Drug Development  ~2 min.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has made remarkable progress in the field of drug development, delighting its investors with a decent 89% return over the past five years....


PFENovember 21, 2024Pfizer Inc. Introduces Groundbreaking Immunotherapy Treatment, Boosting Confidence in PFE Stock  ~2 min.

Pfizer Inc., a leading pharmaceutical company, has announced the development of a groundbreaking immunotherapy treatment that could revolutionize cancer treatment....


PFENovember 11, 2024Pfizer Inc. Announces Groundbreaking Breakthrough in COVID-19 Treatment  ~2 min.

Pfizer Inc., the renowned pharmaceutical company, has made a groundbreaking discovery in the fight against COVID-19....


GSKJanuary 2, 2025GSK PLC introduces groundbreaking technology to revolutionize healthcare industry  ~2 min.

GSK PLC, a leading pharmaceutical company, has unveiled its latest innovation aimed at transforming the healthcare industry....